Guardian Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.35M Sell
3,638
-192
-5% -$195K 0.28% 68
2025
Q4
$3.83M Sell
3,830
-170
-4% -$163K 0.31% 72
2025
Q3
$3.3M Buy
4,000
+12
+0.3% +$8.93K 0.28% 73
2025
Q2
$3.14M Sell
3,988
-1,429
-26% -$1.11M 0.28% 77
2025
Q1
$4.49M Buy
5,417
+1,230
+29% +$1.02M 0.46% 66
2024
Q4
$3.3M Buy
+4,187
New +$3.47M 0.34% 72

Other funds holding LLY

Guardian Partners's LLY Position: Q1 2026 in Review

Guardian Partners reduced its Eli Lilly (LLY) stake by 5% in Q1 2026, selling an estimated $195K and leaving 3,638 shares worth $3.35M. The position accounts for 0.28% of the portfolio, ranked #68.

Guardian Partners first reported a position in LLY in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.49M in Q1 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Guardian Partners held 3,638 shares of Eli Lilly worth $3.35M as of Q1 2026.
  • Guardian Partners sold 192 Eli Lilly shares in Q1 2026, an estimated $195K.
  • Eli Lilly made up 0.28% of Guardian Partners's portfolio in Q1 2026, its #68 holding.
  • Guardian Partners first reported a position in Eli Lilly in Q4 2024 and has held it in 6 quarters since.
  • Guardian Partners's Eli Lilly position peaked at $4.49M in Q1 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Guardian Partners's 13F filing for Q1 2026, filed 18 May 2026.